Adaptimmune Therapeutics plc (ADAP) is priced at $1.33 after the most recent trading session. At the very opening of the session, the stock price was $1.53 and reached a high price of $1.54, prior to closing the session it reached the value of $1.56. The stock touched a low price of $1.33.Recently in News on May 9, 2022, Adaptimmune Reports First Quarter Financial Results and Business Update. – Pooled data from Cohort 1 of the SPEARHEAD-1 trial and the Phase 1 trial of afami-cel in patients with sarcoma to be presented as a poster at ASCO -. You can read further details here
Adaptimmune Therapeutics plc had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $4.1200 on 01/04/22, with the lowest value was $1.3300 for the same time period, recorded on 05/11/22.
Adaptimmune Therapeutics plc (ADAP) full year performance was -72.52%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Adaptimmune Therapeutics plc shares are logging -80.61% during the 52-week period from high price, and -10.14% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.48 and $6.86.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 617729 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Adaptimmune Therapeutics plc (ADAP) recorded performance in the market was -64.53%, having the revenues showcasing -58.18% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 217.15M, as it employees total of 494 workers.
The Analysts eye on Adaptimmune Therapeutics plc (ADAP)
During the last month, 0 analysts gave the Adaptimmune Therapeutics plc a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.5931, with a change in the price was noted -2.28. In a similar fashion, Adaptimmune Therapeutics plc posted a movement of -63.16% for the period of last 100 days, recording 906,331 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ADAP is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical rundown of Adaptimmune Therapeutics plc (ADAP)
Raw Stochastic average of Adaptimmune Therapeutics plc in the period of last 50 days is set at 0.00%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 0.00%. In the last 20 days, the company’s Stochastic %K was 7.92% and its Stochastic %D was recorded 8.95%.
Considering, the past performance of Adaptimmune Therapeutics plc, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -64.53%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -75.86%, alongside a downfall of -72.52% for the period of the last 12 months. The shares increased approximately by -30.37% in the 7-day charts and went down by -28.49% in the period of the last 30 days. Common stock shares were lifted by -58.18% during last recorded quarter.